hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Monoamine oxidases MAO-A and MAO-B play vital roles in the degradation and inactivation of monoamine neurotransmitters such as serotonin and epinephrine. Monoamine oxidases are important drug targets, targeted by MAO inhibitors (MAOIs) such as selegiline. Glutamate dehydrogenase play an important role in oxidative deamination.
==== Mesocorticolimbic pathway ==== Understanding the pathways in which drugs act and how drugs can alter those pathways is key when examining the biological basis of drug addiction. The reward pathway, known as the mesolimbic pathway, or its extension, the mesocorticolimbic pathway, is characterized by the interaction of several areas of the brain. Dopaminergic neurons in the ventral tegmental area (VTA) fire in response to cues that predict a reward and project to the nucleus accumbens through the mesolimbic pathway; nearly all addictive drugs increase dopamine release along this pathway, although they act on it by different routes. The nucleus accumbens, made up largely of GABAergic medium spiny neurons, is a principal target of these projections and is involved in learning conditioned responses to drug-associated cues, and in the growing sensitivity to those cues as addiction progresses. A further target is the prefrontal cortex, including the anterior cingulate and orbitofrontal cortices, which weighs competing information in determining whether a behavior is carried out and forms the associations between drug reward and environmental cues that give those cues their power. These cues are strong mediators of drug-seeking behavior and can trigger relapse even after months or years of abstinence.
A protein called divalent metal transporter 1 (DMT1), which can transport several divalent metals across the plasma membrane, then transports iron across the enterocyte's cell membrane into the cell. If the iron is bound to heme, it is instead transported across the apical membrane by heme carrier protein 1 (HCP1). Heme is then catabolized by microsomal heme oxygenase into biliverdin, releasing Fe2+. These intestinal lining cells can then either store the iron as ferritin, which is accomplished by Fe2+ binding to apoferritin (in which case the iron will leave the body when the cell dies and is sloughed off into feces), or the cell can release it into the body via the only known iron exporter in mammals, ferroportin. Hephaestin, a ferroxidase that can oxidize Fe2+ to Fe3+ and is found mainly in the small intestine, helps ferroportin transfer iron across the basolateral end of the intestine cells. Upon release into the bloodstream, Fe3+ binds transferrin and circulates to tissues. In contrast, ferroportin is post-translationally repressed by hepcidin, a 25-amino acid peptide hormone. The body regulates iron levels by regulating each of these steps. For instance, enterocytes synthesize more Dcytb, DMT1 and ferroportin in response to iron deficiency anemia. Iron absorption from diet is enhanced in the presence of vitamin C and diminished by excess calcium, zinc, or manganese.
=== Cardiac rhythm disease management === Cardiac rhythm disease management (CRDM) is the oldest and largest of Medtronic's business units. Its work in heart rhythm therapies dates back to 1957 when Bakken developed the first wearable heart pacemaker to treat abnormally slow heart rates. Since then, it has expanded its expertise in electrical stimulation to treat other cardiac rhythm diseases. It has also made an effort to address overall disease management by adding diagnostic and monitoring capabilities to many of its devices. An independently-operating Dutch pacemaker manufacturer, Vitatron, acquired by Medtronic in 1986, is now a European subsidiary of the unit. Medtronic and Vitatron pacemakers are interrogated and programmed by Medtronic Carelink Model 2090 Programmer for Medtronic and Vitatron Devices; they use separate interfaces. In 2007, Medtronic recalled its Sprint Fidelis product, the flexible wires, or leads, which connect a defibrillator to the interior of the heart. The leads were found to be failing at an unacceptable rate, resulting in unnecessary shocks or no shocks when needed; either can be lethal. The scope of the problem continues to be a matter of research. Studies since the recall, disputed by Medtronic, suggest that the failure rate of already-implanted Sprint Fidelis leads is increasing exponentially. Medtronic's liability is limited by various court decisions.
=== Computed tomography === Computed tomography angiography has a 98-100% sensitivity and specificity for diagnosing aortic dissections. It is the initial recommended test and also the most commonly used imaging test in the diagnosis of aortic dissections, being utilized in 74-77% of cases in population based studies.
Sources: en.wikipedia.org
==== Premenstrual dysphoric disorder ==== BPD is a psychiatric condition distinguishable from premenstrual dysphoric disorder (PMDD), despite some symptom overlap. BPD affects individuals persistently across all stages of the menstrual cycle, unlike PMDD, which is confined to the luteal phase and ends with menstruation. While PMDD, affecting 3–8% of women, includes mood swings, irritability, and anxiety tied to the menstrual cycle, BPD presents a broader, constant emotional and behavioral challenge irrespective of hormonal changes.
However, much of the white community saw Whitehead as too radical, and soft on what they saw as black extremism. As a result, the UFP was soundly defeated in the primarily white seats by the Rhodesian Front (RF), a newly formed alliance of conservative voices headed by Winston Field and Ian Smith, in what was widely considered a shock result. Field became Prime Minister, with Smith as his deputy.
== Similar lymphoid organs == The spleen and the tonsils are the larger secondary lymphoid organs that serve somewhat similar functions to lymph nodes, though the spleen filters blood cells rather than lymph. The tonsils are sometimes erroneously referred to as lymph nodes. Although the tonsils and lymph nodes do share certain characteristics, there are also many important differences between them, such as their location, structure and size. Furthermore, the tonsils filter tissue fluid whereas lymph nodes filter lymph. The appendix contains lymphoid tissue and is therefore believed to play a role not only in the digestive system, but also in the immune system.
=== Cachexia and sarcopenia === Cachexia and sarcopenia are similar because both cause weight and muscle loss, along with symptoms like weakness and loss of appetite. The difference is sarcopenia is caused by aging, while cachexia happens due to long-term disease and inflammation.
In Buddhism, the Dharma Chakra is widely used to represent the Buddha's Dharma (Buddha's teaching and the universal moral order), Gautama Buddha himself and the walking of the path to enlightenment, since the time of Early Buddhism. The symbol is also sometimes connected to the Four Noble Truths, the Noble Eightfold Path and Dependent Origination. The pre-Buddhist dharmachakra (Pali: dhammacakka) is considered one of the ashtamangala (auspicious signs) in Hinduism and Buddhism and often used as a symbol of both faiths. It is one of the oldest known Indian symbols found in Indian art, appearing with the first surviving post-Indus Valley Civilisation Indian iconography in the time of the Buddhist king Ashoka. The Buddha is said to have set the "wheel of dharma" in motion when he delivered his first sermon, which is described in the Dhammacakkappavattana Sutta. This "turning of the wheel" signifies a great and revolutionary change with universal consequences, brought about by an exceptional human being. Buddhism adopted the wheel as a symbol from the Indian mythical idea of the ideal king, called a chakravartin ("wheel-turner", or "universal monarch"), who was said to possess several mythical objects, including the ratana cakka (the ideal wheel). The Mahā Sudassana Sutta of the Digha Nikaya describes this wheel as having a nave (nābhi), a thousand spokes (sahassārāni) and a felly (nemi), all of which are perfect in every respect.
Sources: en.wikipedia.org
In a cohort of 20 suspected (19 confirmed) head-and-neck squamous cell carcinoma (HNSCC) cases, 68Ga-Trivehexin PET had a higher sensitivity (92.5%), positive predictive value (PPV, 100%), and accuracy (93%) than the standard 18F-FDG PET, for which sensitivity, PPV, and accuracy were 90%, 93.1%, and 84.3%, respectively. 68Ga-Trivehexin was furthermore applied in a case of tonsillar carcinoma metastasized to the brain (see image).
Midtown Raleigh is a relatively new term used to describe the residential and commercial area lying on the northside of the I-440 Beltline and is part of North Raleigh. It is roughly framed by Glenwood/Six Forks Road to the West, Wake Forest Road to the East, and Millbrook Road to the North. It includes shopping centers such as North Hills and Crabtree Valley Mall. It also includes North Hills Park and part of the Raleigh Greenway System. The term was coined by the Greater Raleigh Chamber of Commerce, developer John Kane and planning director Mitchell Silver. The News & Observer newspaper started using the term for marketing purposes only. The Midtown Raleigh Alliance was founded on July 25, 2011, as a way for community leaders to promote the area. The center of the area, especially around the North Hills development at the junction of Six Forks Road and the Beltline, is experiencing rapid urbanization as several high-rise buildings have been built since 2010.
== Pathophysiology == RA primarily starts as a state of persistent cellular activation leading to autoimmunity and immune complexes in joints and other organs where it manifests. The clinical manifestations of disease are primarily inflammation of the synovial membrane and joint damage, and the fibroblast-like synoviocytes play a key role in these pathogenic processes. Three phases of progression of RA are an initiation phase (due to non-specific inflammation), an amplification phase (due to T cell activation), and chronic inflammatory phase, with tissue injury resulting from the cytokines, IL–1, TNF-alpha, and IL–6.
Hyaluronidase increases tissue permeability to accelerate the absorption of other enzymes into tissues. Some snake venoms carry fasciculins, like the mambas (Dendroaspis), which inhibit cholinesterase to make the prey lose muscle control.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.